Pharmaceutical Technology

MAY 9, 2023

Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators. The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).

Pharmaceutical 52

Pharmaceutical 52

European Pharmaceutical Review

SEPTEMBER 8, 2022

“The results consistently showed a clinical and statistical increase in the time between use of intranasal diazepam, Valtoco, over time. The trial enrolled participants aged six to 65 years, in adult patients enrolled, Quality of Life in Epilepsy scores were maintained with increased SEIVALs. days in Period 1 (day 1-90) to 26.8

Safety 90

Safety Medical Patients Pharmaceutical 90

pharmaphorum

OCTOBER 26, 2022

German specialty drugmaker Neuraxpharm has licensed commercial rights in Europe to a wearable device developed by Spanish start-up mjn-neuro that is designed to warn a person with epilepsy about an impending seizure. mjn-SERAS already has a CE mark in Europe and is currently in clinical testing, with results due in 2023.

Pharmacology 64

Pharmacology Patients Sales Healthcare 64

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie.

Safety 95

Safety FDA Management Pharmaceutical 95

Pharmaceutical Technology

JUNE 1, 2023

According to the clinical trial evidence, rimegepant works better to reduce the number of episodic migraines in patients who have previously tried three preventive treatments, compared to a dummy treatment. Up to 145,000 people in England will have the option to choose this treatment.

Side effects 98

Side effects Consulting Education Medicine 98

European Pharmaceutical Review

FEBRUARY 21, 2023

Notably Wakeley explained: “new R&D is opening up the potential of these medicines in new indications, eg, epilepsy and multiple sclerosis (MS).” Arthur Wakeley What data can you share about clinical trials for cannabis-based medicines? James Short What were the key challenges for Celadon during the GMP registration process?

Medicine 130

Medicine Manufacturing Specialization Pharmaceutical 130

European Pharmaceutical Review

DECEMBER 20, 2022

Commenting on fenfluramine, an oral solution developed by biopharma UCB, this “positive CHMP opinion is a significant regulatory milestone towards providing a new treatment option [for] this rare epilepsy in the EU,” explained Mike Davis, Head of Global Epilepsy & Rare Syndromes, UCB.

Safety 85

Safety Medicine Biopharma Patients 85

European Pharmaceutical Review

JUNE 1, 2023

Clinical trial evidence shows that the oral migraine treatment works better than a placebo for reducing the number of episodic migraines in people who have already tried three preventive treatments. These can have significant side-effects and can be ineffective for some people.

Side effects 83

Side effects Medicine Medical Pharmaceutical 83

pharmaphorum

NOVEMBER 25, 2022

Dubbed ONCOVALUE, the initiative will set up a consortium that will develop an artificial intelligence (AI) platform that will be used for routine collection and analysis of clinical data on new oncology medicines to support their assessment by regulators and health technology assessment (HTA) agencies.

Healthcare 90

Healthcare Healthcare Medicine Patients 90

Pharmaceutical Technology

MARCH 1, 2023

NPT-2042 is under clinical development by NeuroPro Therapeutics and currently in Phase I for Seizures. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered as soft-gelatin capsules administered through orally route.

Medical 40

Medical Pharmaceutical Patients 40

European Pharmaceutical Review

APRIL 3, 2023

It relies partly on results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data.

Medicine 85

Medicine Pharmaceutical Marketing Patients 85

European Pharmaceutical Review

MARCH 6, 2023

Keen to learn more about lecanemab’s promising potential to treat the disease, EPR caught up with Dr Michael Irizarry, Senior Vice President of Clinical Research and Deputy Chief Clinical Officer of Alzheimer’s Disease and Brain Health at Eisai. Lecanemab treatment [demonstrated] a 27 percent slowing of [clinical] decline.”

Food and Drug Administration 76

Food and Drug Administration Safety Medicine FDA 76

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on.

Leads 52

Leads Medicine Patients Management 52

pharmaphorum

NOVEMBER 24, 2022

More than two years on, the EU medicines regulator has now selected the first set of data partners to collaborate with DARWIN EU, which focuses on real-world evidence collected on a patient’s health status or delivery of healthcare from a variety of sources, other than conventional clinical trials.

Networking 52

Networking Medicine Healthcare Healthcare 52

Pharmaceutical Technology

MAY 16, 2023

UniQure plans to invest the funds from the royalty rights sale in the development of the company’s pipeline, which includes AMT-130 for Huntington’s disease, AMT-260 for refractory temporal lobe epilepsy, and AMT-162 for SOD-1 ALS. The gene therapy was given a list price of $3.5

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Sales 52

PM360

DECEMBER 14, 2023

The researchers have developed candidate SF001 from the compound and have moved it into Phase 1 clinical trial under biotech Sfunga Therapeutics. “I There are several key advantages of this AI solution that have important clinical relevance,” said Raymond Y. Huang, MD, PhD, Division Chief, Neuroradiology, Brigham and Women’s Hospital.

Healthcare 52

Healthcare Healthcare FDA Education 52

Pharmaceutical Technology

FEBRUARY 13, 2023

While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Lubbers, PhD, chief scientific officer (CSO) of CURE Epilepsy.

Patients 105

Patients Side effects Medical Engineering 105

European Pharmaceutical Review

DECEMBER 1, 2023

So, large molecules such as proteins, peptides, oligonucleotides and enzymes have been evaluated in clinical trials for a variety of different indications. But how do we adapt everything from the development, clinical and manufacturing perspective for these niche indications to address unmet medical needs of the patient population?

Food and Drug Administration 86

Food and Drug Administration Manufacturing Pharma Patients 86

Legacy MEDSearch

OCTOBER 25, 2022

Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs. We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search.

Marketing 52

Marketing FDA Food and Drug Administration Recruitment 52

PM360

AUGUST 21, 2023

Feature Films Cancer Rebellion Credits: Director: Hernan Barangan Matter of Mind: My ALS Credits: Directed by Anna Moot-Levin & Laura Green Produced by David Alvarado, Laura Green, Anna Moot-Levin, Jason Sussberg Securing the Real Mission: Palo Alto Networks for Healthcare Directors: Alex Yakubov, Aiden Fishbein Producers: Aiden Fishbein, Jeff (..)

Networking 40

Networking Doctors Media Management 40

Zymewire

FEBRUARY 8, 2024

Axonis aims to develop first and best-in-class medications for patients living with neurological disorders, with a focus on epilepsies, chronic pain, and neurotraumas. Then once our lead asset s reach the clinic, hopefully, it becomes more logical to fundraise to accelerate research on the earlier programs that were had to deprioritize.

Competition 52

Competition Leads Patients Marketing 52

MedCity News

JANUARY 2, 2024

Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.

Safety 126

Safety Pharma Pharmaceutical Biopharma 126

Legacy MEDSearch

OCTOBER 18, 2022

The company secured $8 million in capital to fund pre-clinical studies with the FDA and to scale up prototypes of its neural implants “as soft as the brain.” Axoft, a neurotechnology company, launched and announced FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.

FDA 98

FDA Engineering Electronics Recruitment 98

Salesforce

APRIL 12, 2023

Using MuleSoft, CHOP has been able to securely pull specific clinical and non-clinical data from various sources. With the pediatric patients in mind, their goal was to unlock data that previously sat in contained silos and distribute it to various stakeholders for that child’s specific needs.

Healthcare 98

Healthcare Healthcare Distribution Ethics 98

PM360

DECEMBER 14, 2022

In its latest venture into the healthcare arena, Amazon is reaching out directly to the consumer via its soon-to-be-launched Amazon Clinic , a virtual health service for patients to see licensed clinicians about common medical issues. The services are cash pay only at this point. Ayogu referred to, Amazon is also in the midst of a $3.9

Manufacturing 52

Manufacturing Medical Healthcare Healthcare 52